



AMERICAN COLLEGE OF SURGEONS

Inspiring Quality:

Highest Standards, Better Outcomes

100+years

CQIP

Cancer Quality Improvement Program



Commission  
on Cancer®

# CQIP

Cancer Quality Improvement Program

St. Rita's Medical Center

6411560

Lima, OH

NCDB

CQIP



## Annual Report 2014

# Table of Contents

[Slide #5: Cancer Program Administrative Reports](#)

[Slide #11: Quality Measure Reports](#)

[Slide #30: Surgical Volume and Unadjusted 30, 90 Day Mortality After Complex Operations](#)

[Slide #38: Survival Reports](#)

[Slide #53: Breast Cancer - Additional Reports](#)

[Slide #63: Colon Cancer - Additional Reports](#)

[Slide #71: Non-Small-Cell Lung Cancer \(NSCLC\) - Additional Reports](#)

[Slide #80: Prostate Cancer - Additional Reports](#)

[Slide #89: Melanoma of the Skin Cancer - Additional Reports](#)

[Slide #97: Commission on Cancer](#)



# Cancer Quality Improvement Program (CQIP)

- A data-driven, process and outcomes-based cancer quality improvement initiative
- Confidentially reports to 1,500 individual CoC-accredited hospitals their data as entered in NCDB (including comparisons with national data from all CoC-accredited programs)
- PDF download provides information to support the reports, technical details, report creation, and scientific justification and references for quality measures
- 2014 release provides CoC-accredited facilities with data on:
  - Compliance with CoC-adopted quality measures
  - Volume data for complex surgical oncology operations with 30-day and 90 day mortality
  - Unadjusted and risk-adjusted survival data for selected cancer sites
  - Other clinical data and administrative data, which will be updated and expanded annually



# CoC Recommendations on the use of the CQIP Report

- The full CQIP report should be presented and discussed at the Cancer Committee meeting
  - Major findings relevant to the cancer program should be listed
  - Interventions for improvement of quality of cancer care should be recommended
- Cancer Committee Leadership should present the report, major findings and recommendations to hospital leadership, including, but not limited to, CEO, COO, CMO, CNO, and bodies such as the Medical Staff Executive Committee, the hospital Quality Committee, etc
- As part of the accreditation process, these processes will be reviewed.



# Cancer Program Administration Reports

## Cancer Program Volume


- Total Case Volume Over Time, 2008–2012
- Insurance Status (including national comparison)

## Cancer Program In/Out Migration

- Total In/Out Migration, 2008-2012 - My Facility
- In/Out Migration by Insurance Status, 2012 - My Facility



# Cancer Program Total Case Volume, 2008 - 2012 My Facility Line Graph




# Cancer Program Total Case Volume, 2008 - 2012 My Facility Data Table

	2008	2009	2010	2011	2012
<b>Breast</b>	129	158	141	142	169
<b>Lung, Bronchus Non-Small Cell Carcinoma</b>	93	91	94	82	95
<b>Prostate</b>	42	68	71	83	74
<b>Colon</b>	54	64	49	69	65
<b>Urinary Bladder</b>	23	29	21	40	49
<b>Kidney and Renal Pelvis</b>	27	27	18	35	33
<b>Lung, Bronchus Small Cell Carcinoma</b>	20	22	21	20	31
<b>Pancreas</b>	16	10	16	12	25
<b>Thyroid</b>	14	16	31	25	24
<b>NHL - Nodal</b>	19	23	15	23	23
<b>All Other Sites</b>	188	223	191	202	229
<b>TOTAL</b>	625	731	668	733	817



# Insurance Status, 2009 - 2012 - My Facility vs. All CoC




	2009 My Facility	2010 My Facility	2011 My Facility	2012 My Facility	2012 All CoC
<b>Not Insured</b>	5.47 % (n=40)	5.24 % (n=35)	4.77 % (n=35)	5.75 % (n=47)	3.55 % (n=41344)
<b>Private/ Managed</b>	34.75 % (n=254)	37.28 % (n=249)	33.56 % (n=246)	33.41 % (n=273)	39.37 % (n=458231)
<b>Medicaid</b>	3.83 % (n=28)	4.19 % (n=28)	3.14 % (n=23)	4.53 % (n=37)	6.1 % (n=70956)
<b>Medicare</b>	54.58 % (n=399)	51.65 % (n=345)	57.03 % (n=418)	54.35 % (n=444)	45.96 % (n=534842)
<b>Other Government</b>	0.14 % (n=1)	0.75 % (n=5)	0.14 % (n=1)	0.24 % (n=2)	2.87 % (n=33452)
<b>Insurance Status Unknown</b>	1.23 % (n=9)	0.9 % (n=6)	1.36 % (n=10)	1.71 % (n=14)	2.14 % (n=24958)






# Total In/Out Migration, 2008 - 2012 - My Facility



	2008	2009	2010	2011	2012
<b>Diagnosed Here and Treated Elsewhere</b>	5.44 % (n=34)	5.61 % (n=41)	7.34 % (n=49)	9.41 % (n=69)	12.12 % (n=99)
<b>Diagnosed and Treated Here</b>	70.72 % (n=442)	74.97 % (n=548)	71.26 % (n=476)	71.08 % (n=521)	61.57 % (n=503)
<b>Diagnosed Elsewhere and Treated Here</b>	23.84 % (n=149)	19.43 % (n=142)	21.41 % (n=143)	19.51 % (n=143)	26.32 % (n=215)



# In/Out Migration by Insurance Status, 2012 - My Facility



	Not Insured	Private/Managed	Medicaid	Medicare	Other Government	Unknown
Diagnosed Here and Treated Elsewhere	1.1 % (n=9)	4.8 % (n=39)	0.2 % (n=2)	5.9 % (n=48)	0 % (n=0)	0.1 % (n=1)
Diagnosed and Treated Here	2.8 % (n=23)	19 % (n=155)	3.4 % (n=28)	35.1 % (n=287)	0.1 % (n=1)	1.1 % (n=9)
Diagnosed Elsewhere and Treated Here	1.8 % (n=15)	9.7 % (n=79)	0.9 % (n=7)	13.3 % (n=109)	0.1 % (n=1)	0.5 % (n=4)

# Quality Measure Reports

## Accountability Measure

- Considered the current standard of care based on clinical trial evidence Commission on Cancer Standard 4.4.

## Quality Improvement Measure (QI)

- Demonstrates good practice based on consensus. Usually not based on clinical trial evidence. Commission on Cancer Standard 4.5 addresses compliance with quality improvement.

## Surveillance Measure

- Used at the community, regional, and/or national level to monitor patterns and trends of care in order to guide policymaking and resource allocation.



# Cancer Program Practice Profile (CP<sup>3</sup>R ) Estimated Performance Rates

- Breast (6)
- Colon (2)
- Rectum (1)
- Non-Small Cell Lung (2)
- Gastric (1)

Extensive assessment and validation of the measures were performed using cancer registry data reported to the National Cancer Data Base (NCDB).

**Disclaimer: All measures are designed to assess performance at the hospital or systems-level, and are not intended for application to individual physician performance.**




# Quality Measure Reports – Breast

- **BCSRT:** Breast radiation after breast conserving surgery (NQF 0219 – Accountability Measure)
- **MAC:** Combination chemotherapy for hormone receptor negative breast cancer (NQF 0559 – Accountability Measure)
- **HT:** Adjuvant hormonal therapy for hormone receptor positive breast cancer (NQF 0220 – Accountability Measure)
- **BCS:** Breast conserving surgery rate (Surveillance Measure)
- **MASRT:** Radiation therapy considered or administered following mastectomy within 1 year of diagnosis for women with 4 or more positive regional lymph nodes (Accountability Measure)
- **nBx:** Image or palpation-guided needle biopsy (core or FNA) is performed for the diagnosis of breast cancer (Quality Improvement Measure)

NQF = National Quality Forum Endorsed Measure




# BREAST, 2012, BCSRT: Breast radiation after breast conserving surgery (NQF 0219 - Accountability Measure)



	My Program	My State (OH)	My Census Region (East North Central)	My ACS Division (East Central)	My CoC Program Type (COMP)	All CoC Programs
<b>Performance Rate</b>	90 %	92.2 %	93.2 %	93.4 %	90.8 %	90.3 %

Radiation therapy is administered within 1 year (365 days) of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer. (CP3R data as of 12/12/2014)


# BREAST, 2012, MAC: Combination chemotherapy for hormone receptor negative breast cancer (NQF 0559 - Accountability Measure)



	My Program	My State (OH)	My Census Region (East North Central)	My ACS Division (East Central)	My CoC Program Type (COMP)	All CoC Programs
<b>Performance Rate</b>	100 %	93.9 %	93.5 %	93.1 %	92 %	90.8 %

Combination chemotherapy is considered or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0M0, or Stage II or III hormone receptor negative breast cancer. (CP3R data as of 12/12/2014)

# BREAST, 2012, HT: Adjuvant hormonal therapy for hormone receptor positive breast cancer (NQF 0220 - Accountability Measure)




	My Program	My State (OH)	My Census Region (East North Central)	My ACS Division (East Central)	My CoC Program Type (COMP)	All CoC Programs
<b>Performance Rate</b>	96.2 %	92.5 %	91.4 %	92.6 %	88.3 %	87.7 %

Tamoxifen or third generation aromatase inhibitor is considered or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0, or stage IB - III hormone receptor positive breast cancer. (CP3R data as of 12/12/2014)




# BREAST, 2012, BCS: Breast conserving surgery rate (Surveillance Measure)



	My Program	My State (OH)	My Census Region (East North Central)	My ACS Division (East Central)	My CoC Program Type (COMP)	All CoC Programs
<b>Performance Rate</b>	64 %	64.8 %	65.1 %	67.1 %	62.9 %	63 %

Breast conservation surgery rate for women with AJCC clinical stage 0, I, or II breast cancer. (CP3R data as of 12/12/2014)


# BREAST, 2012, MASRT: Radiation therapy considered or administered following mastectomy within 1 year of diagnosis for women with 4 or more positive regional lymph nodes



	My Program	My State (OH)	My Census Region (East North Central)	My ACS Division (East Central)	My CoC Program Type (COMP)	All CoC Programs
<b>Performance Rate</b>	77.8 %	88.4 %	88.5 %	90.8 %	84.9 %	84.5 %

Radiation therapy is considered or administered following any mastectomy within 1 year (365 days) of diagnosis of breast cancer for women with  $\geq 4$  positive regional lymph nodes. (CP3R data as of 12/12/2014)

# BREAST, 2012, nBx: Image or palpation-guided needle biopsy (core or FNA) is performed for the diagnosis of breast cancer (Quality Improvement Measure)



	My Program	My State (OH)	My Census Region (East North Central)	My ACS Division (East Central)	My CoC Program Type (COMP)	All CoC Programs
<b>Performance Rate</b>	93.6 %	83.5 %	87.7 %	87.4 %	87.7 %	87.6 %

Image or palpation-guided needle biopsy (core or FNA) is performed to establish diagnosis of breast cancer. (CP3R data as of 12/12/2014)


# Quality Measure Reports - Colon

- **ACT:** Adjuvant chemotherapy for lymph node positive colon cancer (NQF 0223 – Accountability Measure)
- **12RL:** At least 12 lymph nodes are removed and examined as part of primary colon cancer resection (NQF 0225 – Quality Improvement Measure)

NQF = National Quality Forum Endorsed Measure



# COLON, 2012, ACT: Adjuvant chemotherapy for lymph node positive colon cancer (NQF 0223 - Accountability Measure)




	My Program	My State (OH)	My Census Region (East North Central)	My ACS Division (East Central)	My CoC Program Type (COMP)	All CoC Programs
<b>Performance Rate</b>	100 %	89.3 %	91.3 %	90.2 %	87.7 %	86.4 %

Adjuvant chemotherapy is considered or administered within 4 months (120 days) of diagnosis for patients under the age of 80 with AJCC Stage III (lymph node positive) colon cancer. (CP3R data as of 12/12/2014)



# COLON, 2012, 12RL: At least 12 regional lymph nodes removed and pathologically examined for resected colon cancer (NQF 0225 - Quality Improvement Measure)



	My Program	My State (OH)	My Census Region (East North Central)	My ACS Division (East Central)	My CoC Program Type (COMP)	All CoC Programs
<b>Performance Rate</b>	84.4 %	87.5 %	89.2 %	87.1 %	87.8 %	88.1 %


At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer. (CP3R data as of 12/12/2014)

# Quality Measure Reports - Rectum

- **RECRT:** Radiation therapy is administered as a component of therapy along with surgical resection (Surveillance Measure)



# RECTUM, 2012, RECRT: Radiation therapy is administered as a component of therapy with surgical resection (Surveillance Measure)



	My Program	My State (OH)	My Census Region (East North Central)	My ACS Division (East Central)	My CoC Program Type (COMP)	All CoC Programs
<b>Performance Rate</b>	100 %	91.8 %	91.1 %	90.9 %	89.4 %	89.2 %

Radiation therapy is considered or administered within 6 months (180 days) of diagnosis for patients under the age of 80 of with clinical or pathologic AJCC T4N0M0 or Stage III receiving surgical resection for rectal cancer. (CP3R data as of 12/12/2014)




# Quality Measure Reports - Non-Small Cell Lung

- **10RLN:** At least 10 regional lymph nodes removed and pathologically examined for AJCC stage IA, IB, IIA, and IIB resected NSCLC (Surveillance Measure)
- **LT:** Systemic chemotherapy is administered or considered within 4 months prior to surgery or within 6 months postoperatively for surgically resected cases with pathologic, lymph node-positive (pN1) and (pN2) NSCLC (Quality Improvement Measure)




# NSCLC, 2012, 10RLN: At least 10 regional lymph nodes removed and pathologically examined for AJCC stage IA, IB, IIA, and IIB resected NSCLC (Surveillance Measure)



	My Program	My State (OH)	My Census Region (East North Central)	My ACS Division (East Central)	My CoC Program Type (COMP)	All CoC Programs
<b>Performance Rate</b>	33.3 %	36.4 %	38.7 %	44.8 %	35.5 %	39.6 %

At least 10 regional lymph nodes are removed and pathologically examined for AJCC stage IA, IB, IIA, and IIB resected NSCLC. (CP3R data as of 12/12/2014)

# NSCLC, 2012, LCT: Systemic chemotherapy administered or considered 4 months prior surgery or 6 months postoperatively resected cases with pN1 or pN2 (Quality Improvement Measure)



	My Program	My State (OH)	My Census Region (East North Central)	My ACS Division (East Central)	My CoC Program Type (COMP)	All CoC Programs
<b>Performance Rate</b>	NA	86.9 %	89.9 %	89.8 %	83.8 %	84.7 %


Systemic chemotherapy administered within 4 months to day preoperatively or day of surgery to 6 months postoperatively, or it is considered for surgically resected cases with pathologic, lymph node-positive (pN1) or (pN2) NSCLC.(CP3R data as of 12/12/2014)

# Quality Measure Reports - Gastric

- **G15RLN:** At least 15 regional lymph nodes are removed and pathologically examined for resected gastric cancer (Quality Improvement Measure)



# Gastric, 2012, G15RLN: At least 15 regional lymph nodes are removed and pathologically examined for resected gastric cancer (Quality Improvement Measure)



	My Program	My State (OH)	My Census Region (East North Central)	My ACS Division (East Central)	My CoC Program Type (COMP)	All CoC Programs
<b>Performance Rate</b>	NA	49 %	54.2 %	49.8 %	45.7 %	52.7 %


At least 15 regional lymph nodes are removed and pathologically examined for resected gastric cancer. (CP3R data as of 12/12/2014)

# Volume and Unadjusted 30, 90 Day Mortality After Selected Complex Cancer Operations

- Cystectomy
- Esophagectomy
- Gastrectomy
- Pancreatectomy
- Rectal resection
- Lung resection



# Number of Major Surgical Resections for Selected Cancers, 2010 - 2012 - My Facility




	Cystectomy	Esophagectomy	Gastrectomy	Rectal Resection	Pancreatectomy	Lung Resection
<b>2010 Diagnosis Year</b>	0	0	0	2	0	20
<b>2011 Diagnosis Year</b>	3	0	2	6	0	27
<b>2012 Diagnosis Year</b>	2	0	1	7	0	20

\* includes surgery codes 30-80 only



# Cystectomies, Unadjusted 30, 90 Day Mortality, 95% CI, 2010 - 2012 My Facility vs. All CoC and CoC High Volume




	My Facility		All CoC		CoC High Volume	
	30 Day	90 Day	30 Day	90 Day	30 Day	90 Day
<b>Mortality Percent</b>	0.0%	0.0%	2.5%	7.0%	2.0%	6.4%
<b>95 % CI</b>	(0.0,59.9)	(0.0,59.9)	(2.3,2.7)	(6.6,7.3)	(1.8,2.3)	(6.0,6.9)
<b>Deaths</b>	0	0	428	1,147	200	590
<b>Resections</b>	5	5	17,399	16,450	9,817	9,186

\*NA No resections, or < 30 or < 90 days of follow up for alive patients





# Esophagectomies, Unadjusted 30, 90 Day Mortality, 95% CI, 2010 - 2012 My Facility vs. All CoC and CoC High Volume




	My Facility		All CoC		CoC High Volume	
	30 Day	90 Day	30 Day	90 Day	30 Day	90 Day
<b>Mortality Percent</b>	*NA	*NA	3.7%	8.5%	2.4%	6.6%
<b>95 % CI</b>	*NA	*NA	(3.4,4.1)	(8.0,9.1)	(2.0,2.9)	(5.8,7.3)
<b>Deaths</b>	*NA	*NA	287	610	84	212
<b>Resections</b>	*NA	*NA	7,680	7,159	3,529	3,236

\*NA No resections, or < 30 or < 90 days of follow up for alive patients



# Gastrectomies, Unadjusted 30, 90 Day Mortality, 95% CI, 2010 - 2012 My Facility vs. All CoC and CoC High Volume




	My Facility		All CoC		CoC High Volume	
	30 Day	90 Day	30 Day	90 Day	30 Day	90 Day
<b>Mortality Percent</b>	50.0%	50.0%	4.0%	8.2%	2.7%	6.0%
<b>95 % CI</b>	(2.6,100.0)	(2.6,100.0)	(3.8,4.2)	(7.9,8.6)	(2.5,3.0)	(5.6,6.4)
<b>Deaths</b>	1	1	769	1,502	273	564
<b>Resections</b>	2	2	19,219	18,298	9,983	9,383

\*NA No resections, or < 30 or < 90 days of follow up for alive patients



# Lung Resections, Unadjusted 30, 90 Day Mortality, 95% CI, 2010-2012 My Facility vs. All CoC and CoC High Volume




	My Facility		All CoC		CoC High Volume	
	30 Day	90 Day	30 Day	90 Day	30 Day	90 Day
<b>Mortality Percent</b>	9.4%	10.9%	2.5%	5.0%	2.5%	4.9%
<b>95 % CI</b>	(4.1,18.5)	(5.1,20.5)	(2.4,2.6)	(4.9,5.1)	(2.4,2.6)	(4.8,5.1)
<b>Deaths</b>	6	7	1,926	3,645	1,737	3,290
<b>Resections</b>	64	64	75,850	73,012	69,139	66,515

\*NA No resections, or < 30 or < 90 days of follow up for alive patients




# Pancreatectomies, Unadjusted 30, 90 Day Mortality, 95% CI, 2010 - 2012 My Facility vs. All CoC and CoC High Volume



	My Facility		All CoC		CoC High Volume	
	30 Day	90 Day	30 Day	90 Day	30 Day	90 Day
<b>Mortality Percent</b>	*NA	*NA	3.0%	6.4%	2.5%	5.4%
<b>95 % CI</b>	*NA	*NA	(2.8,3.2)	(6.1,6.8)	(2.2,2.7)	(5.1,5.7)
<b>Deaths</b>	*NA	*NA	573	1,175	335	702
<b>Resections</b>	*NA	*NA	19,059	18,255	13,659	13,016

\*NA No resections, or < 30 or < 90 days of follow up for alive patients

# Rectal Resections, Unadjusted 30, 90 Day Mortality, 95% CI, 2010 - 2012 My Facility vs. All CoC and CoC High Volume



	My Facility		All CoC		CoC High Volume	
	30 Day	90 Day	30 Day	90 Day	30 Day	90 Day
<b>Mortality Percent</b>	0.0%	7.1%	1.5%	3.0%	1.2%	2.6%
<b>95 % CI</b>	(0.0,20.0)	(0.4,33.9)	(1.4,1.6)	(2.9,3.2)	(1.1,1.4)	(2.5,2.8)
<b>Deaths</b>	0	1	484	930	270	540
<b>Resections</b>	15	14	32,640	30,825	21,816	20,490

\*NA No resections, or < 30 or < 90 days of follow up for alive patients

# Survival Reports

CQIP contains both unadjusted survival rates and risk-adjusted hazard ratios for breast, colon, and non-small cell lung cancer primaries diagnosed between 2005 and 2007.

*These reports are intended for internal institutional use only, with the goal of better understanding your program's performance while identifying opportunities for improved cancer care.*

To be eligible for a survival report, your cancer program must have:

- administered all or part of patient treatment, or made a decision not to treat
- accrued 30 or more cases during the reporting period for breast, colon, and lung primaries within disease site and stage.




# Unadjusted Survival

- Unadjusted survival rates are calculated by the life table method
- Program-specific rates relative to aggregated CoC are stage-stratified and include 95% confidence intervals.
- Data are for patients who received all treatment at your facility (“All”), and for those who received only some of the therapy at your facility (“Partial”)
- Please note that survival data are not available for Network-level CQIP Reports
- CoC policy does not allow cancer programs to publicly report survival rates for their facility generated from NCDB data on any website or publication



# Unadjusted 5 Year Survival Rates 2005 - 2007: Breast Cancer Stages I, II




	'Partial' Rx, Stage I		'All' Rx, Stage I		'Partial' Rx Stage II		'All' Rx Stage II	
	My Prog	All CoC	My Prog	All CoC	My Prog	All CoC	My Prog	All CoC
<b>Unadjusted Survival</b>	94.2%	90.5%	94.3%	90.0%	86.6%	84.3%	87.4%	83.4%
<b>95 % CI</b>	(90.6,98.0)	(90.3,90.6)	(90.4,98.5)	(89.9,90.2)	(79.2,94.7)	(84.1,84.5)	(79.7,96.0)	(83.1,83.6)
<b>Deaths</b>	9	18,535	7	15,008	10	20,904	8	17,221
<b>Total Cases</b>	159	205,242	127	160,105	75	139,887	64	109,574

CoC policy does not allow cancer programs to publicly report survival rates for their facility generated from NCDB data. \*NA denotes <30 cumulative cases &/or the cancer program has not submitted at least 5 years of data to the NCDB(new programs).






# Unadjusted 5 Year Survival Rates 2005 - 2007: Breast Cancer Stages III, IV



	'Partial' Rx, Stage III		'All' Rx, Stage III		'Partial' Rx Stage IV		'All' Rx Stage IV	
	My Prog	All CoC	My Prog	All CoC	My Prog	All CoC	My Prog	All CoC
<b>Unadjusted Survival</b>	60.0%	66.9%	*NA	64.9%	*NA	23.0%	*NA	21.0%
<b>95 % CI</b>	(44.8,80.4)	(66.5,67.3)	*NA	(64.5,65.4)	*NA	(22.4,23.6)	*NA	(20.4,21.7)
<b>Deaths</b>	12	16,708	10	13,684	10	14,209	9	12,450
<b>Total Cases</b>	30	52,710	26	40,968	16	19,035	15	16,305

CoC policy does not allow cancer programs to publicly report survival rates for their facility generated from NCDB data. \*NA denotes <30 cumulative cases &/or the cancer program has not submitted at least 5 years of data to the NCDB(new programs).


# Unadjusted 5 Year Survival Rates 2005 - 2007: Colon Cancer Stages I, II



	'Partial' Rx, Stage I		'All' Rx, Stage I		'Partial' Rx Stage II		'All' Rx Stage II	
	My Prog	All CoC	My Prog	All CoC	My Prog	All CoC	My Prog	All CoC
<b>Unadjusted Survival</b>	73.6%	74.1%	72.8%	73.8%	67.9%	64.4%	64.8%	63.6%
<b>95 % CI</b>	(60.1,90.1)	(73.7,74.5)	(59.0,89.8)	(73.4,74.3)	(53.9,85.5)	(64.0,64.8)	(49.9,84.0)	(63.2,64.1)
<b>Deaths</b>	9	10,624	9	9,580	11	17,940	11	16,322
<b>Total Cases</b>	36	43,412	35	38,871	35	53,104	32	47,424

CoC policy does not allow cancer programs to publicly report survival rates for their facility generated from NCDB data. \*NA denotes <30 cumulative cases &/or the cancer program has not submitted at least 5 years of data to the NCDB(new programs).


# Unadjusted 5 Year Survival Rates 2005 - 2007: Colon Cancer Stages III, IV



	'Partial' Rx, Stage III		'All' Rx, Stage III		'Partial' Rx Stage IV		'All' Rx Stage IV	
	My Prog	All CoC	My Prog	All CoC	My Prog	All CoC	My Prog	All CoC
<b>Unadjusted Survival</b>	54.9%	53.7%	54.9%	52.4%	*NA	10.9%	*NA	10.0%
<b>95 % CI</b>	(42.2,71.4)	(53.3,54.2)	(42.2,71.4)	(52.0,52.9)	*NA	(10.6,11.2)	*NA	(9.7,10.3)
<b>Deaths</b>	21	22,358	21	20,296	24	32,095	24	29,373
<b>Total Cases</b>	48	50,361	48	44,615	26	36,944	26	33,529

CoC policy does not allow cancer programs to publicly report survival rates for their facility generated from NCDB data. \*NA denotes <30 cumulative cases &/or the cancer program has not submitted at least 5 years of data to the NCDB(new programs).

# Unadjusted 1 Year Survival Rates 2005 - 2007: NSCLC Stages I, II




	'Partial' Rx, Stage I		'All' Rx, Stage I		'Partial' Rx Stage II		'All' Rx Stage II	
	My Prog	All CoC	My Prog	All CoC	My Prog	All CoC	My Prog	All CoC
<b>Unadjusted Survival</b>	75.4%	84.2%	72.1%	82.8%	*NA	70.7%	*NA	68.4%
<b>95 % CI</b>	(65.9,86.2)	(83.9,84.5)	(61.7,84.3)	(82.5,83.1)	*NA	(70.1,71.3)	*NA	(67.7,69.1)
<b>Deaths</b>	45	39,523	41	32,996	13	15,135	13	12,561
<b>Total Cases</b>	69	80,207	61	65,686	14	22,193	14	17,989

CoC policy does not allow cancer programs to publicly report survival rates for their facility generated from NCDB data. \*NA denotes <30 cumulative cases &/or the cancer program has not submitted at least 5 years of data to the NCDB(new programs).



# Unadjusted 1 Year Survival Rates 2005 - 2007: NSCLC Stages III,IV



	'Partial' Rx, Stage III		'All' Rx, Stage III		'Partial' Rx Stage IV		'All' Rx Stage IV	
	My Prog	All CoC	My Prog	All CoC	My Prog	All CoC	My Prog	All CoC
<b>Unadjusted Survival</b>	47.8%	50.1%	47.5%	47.4%	18.9%	24.9%	16.0%	23.4%
<b>95 % CI</b>	(37.2,61.4)	(49.8,50.5)	(36.5,61.9)	(47.0,47.8)	(12.9,27.8)	(24.6,25.1)	(10.4,24.8)	(23.2,23.7)
<b>Deaths</b>	60	64,689	55	55,547	109	107,564	105	94,952
<b>Total Cases</b>	67	76,219	61	64,387	111	112,914	106	99,341


CoC policy does not allow cancer programs to publicly report survival rates for their facility generated from NCDB data. \*NA denotes <30 cumulative cases &/or the cancer program has not submitted at least 5 years of data to the NCDB(new programs).

# Risk Adjusted Survival

- Site and stage specific Hazard Ratios (HR) adjusted for age, race, sex, cancer sequence, insurance status, and comorbid conditions are generated for your program
- HR are generated for patients who received All Treatment in your facility, and for patients who received Partial Treatment in your facility
- An HR < 1.0 indicates a lower risk of death and a HR > 1.0 indicates a higher risk of death at your facility compared to all CoC patients
- An HR above or below 1.0 for your program is not statistically significant unless stated
- Please note that survival data are not available for Network-level CQIP Reports



# Risk-Adjusted Survival Breast Cancer Stage Stratified Hazard Ratios 2005 - 2007



	Stage I - All	Stage I - Partial	Stage II - All	Stage II - Partial	Stage III - All	Stage III - Partial	Stage IV - All	Stage IV - Partial
<b>Hazard Ratio</b>	0.78	0.87	0.96	0.93	*NA	1.11	*NA	*NA
<b>95 % CI</b>	(0.54,1.11)	(0.68,1.12)	(0.77,1.2)	(0.68,1.27)	*NA	(0.76,1.61)	*NA	*NA
<b>Deaths</b>	7	9	8	10	10	12	9	10
<b>Total Cases</b>	127	159	64	75	26	30	15	16
<b>Significance</b>	**NS	**NS	**NS	**NS	*NA	**NS	*NA	*NA

CoC policy does not allow cancer programs to publicly report survival rates for their facility generated from NCDB data. \*NA denotes <30 cumulative cases &/or the cancer program has not submitted at least 5 years of data. \*\*NS denotes "Non-Significant"

Lower (Worse) Survival Hazard Ratio > 1  
Higher (Better) Survival Hazard Ratio < 1



# Risk Adjusted Survival Breast Cancer: Patient Demographics 2005 - 2007 - My Facility


Program administered 'all' treatment				
	Stage I	Stage II	Stage III	Stage IV
Patient N	127	64	26	15
Death N	7	8	10	9
Proportion Lost to Follow-Up	7.1%	3.1%	0.0%	0.0%
Proportion Missing Race or Payer Data	0.0%	3.1%	0.0%	0.0%
Program administered 'partial' treatment				
	Stage I	Stage II	Stage III	Stage IV
Patient N	159	75	30	16
Death N	9	10	12	10
Proportion Lost to Follow-Up	6.3%	2.7%	0.0%	0.0%
Proportion Missing Race or Payer Data	0.0%	2.7%	0.0%	0.0%

CoC policy does not allow cancer programs to publicly report survival rates for their facility generated from NCDDB data. \*NA denotes <30 cumulative cases &/or the cancer program has not submitted at least 5 years of data.





# Risk-Adjusted Survival Colon Cancer Stage Stratified Hazard Ratios 2005 - 2007



	Stage I - All	Stage I - Partial	Stage II - All	Stage II - Partial	Stage III - All	Stage III - Partial	Stage IV - All	Stage IV - Partial
<b>Hazard Ratio</b>	0.98	0.98	0.99	0.96	0.97	0.97	*NA	*NA
<b>95 % CI</b>	(0.79,1.22)	(0.79,1.21)	(0.69,1.41)	(0.68,1.35)	(0.78,1.2)	(0.78,1.21)	*NA	*NA
<b>Deaths</b>	9	9	11	11	21	21	24	24
<b>Total Cases</b>	35	36	32	35	48	48	26	26
<b>Significance</b>	**NS	**NS	**NS	**NS	**NS	**NS	*NA	*NA

CoC policy does not allow cancer programs to publicly report survival rates for their facility generated from NCDB data. \*NA denotes <30 cumulative cases &/or the cancer program has not submitted at least 5 years of data. \*\*NS denotes "Non-Significant"

Lower (Worse) Survival Hazard Ratio > 1  
Higher (Better) Survival Hazard Ratio < 1


# Risk Adjusted Survival Colon Cancer: Patient Demographics 2005 - 2007 - My Facility

Program administered 'all' treatment				
	Stage I	Stage II	Stage III	Stage IV
Patient N	35	32	48	26
Death N	9	11	21	24
Proportion Lost to Follow-Up	11.4%	9.4%	14.6%	7.7%
Proportion Missing Race or Payer Data	2.9%	3.1%	2.1%	0.0%
Program administered 'partial' treatment				
	Stage I	Stage II	Stage III	Stage IV
Patient N	36	35	48	26
Death N	9	11	21	24
Proportion Lost to Follow-Up	11.1%	11.4%	14.6%	7.7%
Proportion Missing Race or Payer Data	2.8%	2.9%	2.1%	0.0%

CoC policy does not allow cancer programs to publicly report survival rates for their facility generated from NCDDB data. \*NA denotes <30 cumulative cases &/or the cancer program has not submitted at least 5 years of data.



# Risk-Adjusted Survival NSCLC Cancer Stage Stratified Hazard Ratios 2005 - 2007



	Stage I - All	Stage I - Partial	Stage II - All	Stage II - Partial	Stage III - All	Stage III - Partial	Stage IV - All	Stage IV - Partial
<b>Hazard Ratio</b>	1.11	1.18	*NA	*NA	1.01	1.01	1.01	1
<b>95 % CI</b>	(0.91,1.35)	(0.96,1.46)	*NA	*NA	(0.88,1.15)	(0.88,1.16)	(0.92,1.1)	(0.92,1.1)
<b>Deaths</b>	41	45	13	13	55	60	105	109
<b>Total Cases</b>	61	69	14	14	61	67	106	111
<b>Significance</b>	**NS	**NS	*NA	*NA	**NS	**NS	**NS	**NS

CoC policy does not allow cancer programs to publicly report survival rates for their facility generated from NCDB data. \*NA denotes <30 cumulative cases &/or the cancer program has not submitted at least 5 years of data. \*\*NS denotes "Non-Significant"  
 Lower (Worse) Survival Hazard Ratio > 1  
 Higher (Better) Survival Hazard Ratio < 1

# Risk Adjusted Survival NSCLC Cancer: Patient Demographics 2005 - 2007 - My Facility

Program administered 'all' treatment				
	Stage I	Stage II	Stage III	Stage IV
Patient N	61	14	61	106
Death N	41	13	55	105
Proportion Lost to Follow-Up	3.3%	0.0%	0.0%	0.0%
Proportion Missing Race or Payer Data	0.0%	0.0%	0.0%	1.9%
Program administered 'partial' treatment				
	Stage I	Stage II	Stage III	Stage IV
Patient N	69	14	67	111
Death N	45	13	60	109
Proportion Lost to Follow-Up	2.9%	0.0%	0.0%	0.0%
Proportion Missing Race or Payer Data	0.0%	0.0%	0.0%	1.8%

CoC policy does not allow cancer programs to publicly report survival rates for their facility generated from NCDDB data. \*NA denotes <30 cumulative cases &/or the cancer program has not submitted at least 5 years of data.




# Breast Cancer—Additional Reports

- Stage Distribution
- In/Out Migration
- In/Out Migration by Insurance Status
- Insurance Status
- Distance Traveled
- First Course Treatment – Stage I
- Days to First Treatment: Cases Diagnosed and Treated at My Facility
- Days to First Treatment: Cases Diagnosed at My Facility or Elsewhere; Treated at My Facility
- Radiation Treatment After Breast Cancer Surgery Out Migration Heat Map By Zip Code




# Stage Distribution - Breast Cancer Diagnosed in 2012, My Facility vs. All CoC



	0	I	II	III	IV	NA	UNK
My Facility	19.53 % (n=33)	36.69 % (n=62)	29.59 % (n=50)	5.92 % (n=10)	4.14 % (n=7)	0.59 % (n=1)	3.55 % (n=6)
All CoC	20.63 % (n=45169)	41.59 % (n=91068)	24.01 % (n=52568)	7.96 % (n=17424)	3.87 % (n=8465)	0.07 % (n=164)	1.87 % (n=4094)


# In/Out Migration Breast Cancer, 2010 - 2012 - My Facility



	2010	2011	2012
<b>Diagnosed Here and Treated Elsewhere</b>	4.96 % (n=7)	11.27 % (n=16)	9.47 % (n=16)
<b>Diagnosed and Treated Here</b>	69.5 % (n=98)	69.72 % (n=99)	63.91 % (n=108)
<b>Diagnosed Elsewhere and Treated Here</b>	25.53 % (n=36)	19.01 % (n=27)	26.63 % (n=45)



# In/Out Migration by Insurance Status Breast Cancer, 2012 My Facility




	Not Insured	Private/Managed	Medicaid	Medicare	Other Government	Unknown
Diagnosed Here and Treated Elsewhere	0.6 % (n=1)	7.1 % (n=12)	0 % (n=0)	1.8 % (n=3)	0 % (n=0)	0 % (n=0)
Diagnosed and Treated Here	4.7 % (n=8)	31.4 % (n=53)	5.3 % (n=9)	21.9 % (n=37)	0 % (n=0)	0.6 % (n=1)
Diagnosed Elsewhere and Treated Here	2.4 % (n=4)	11.8 % (n=20)	1.8 % (n=3)	10.1 % (n=17)	0 % (n=0)	0.6 % (n=1)





# Insurance Status - Breast Cancer, 2009 - 2012


## My Facility vs. All CoC



	2009 My Facility	2010 My Facility	2011 My Facility	2012 My Facility	2012 All CoC
<b>Not Insured</b>	5.7 % (n=9)	1.42 % (n=2)	2.82 % (n=4)	7.69 % (n=13)	2.3 % (n=5046)
<b>Private/Managed</b>	50.63 % (n=80)	50.35 % (n=71)	49.3 % (n=70)	50.3 % (n=85)	50.84 % (n=111324)
<b>Medicaid</b>	5.06 % (n=8)	6.38 % (n=9)	4.23 % (n=6)	7.1 % (n=12)	6.29 % (n=13774)
<b>Medicare</b>	37.97 % (n=60)	39.72 % (n=56)	42.96 % (n=61)	33.73 % (n=57)	37.28 % (n=81623)
<b>Other Government</b>	0 % (n=0)	0.71 % (n=1)	0 % (n=0)	0 % (n=0)	1.34 % (n=2928)
<b>Insurance Status Unknown</b>	0.63 % (n=1)	1.42 % (n=2)	0.7 % (n=1)	1.18 % (n=2)	1.94 % (n=4257)




# Distance Traveled - Breast Cancer, 2012



	< 5 miles	5-9 miles	10-24 miles	25-49 miles	50-99 miles	>=100 miles	Unknown
My Facility	15.98 % (n=27)	21.3 % (n=36)	36.69 % (n=62)	25.44 % (n=43)	0.59 % (n=1)	0 % (n=0)	0 % (n=0)
All CoC	19.03 % (n=41658)	23.85 % (n=52216)	33.46 % (n=73253)	14 % (n=30656)	5.93 % (n=12984)	3.2 % (n=7004)	0.54 % (n=1181)

# First Course Treatment Stage I Breast Cancer, 2012


## My Facility vs. All CoC



	Surgery Only	Surgery & Radiation	Surgery & Chemotherapy	Surgery, Radiation & Chemotherapy	Surgery, Radiation & Hormone Therapy	Surgery & Hormone Therapy	Surgery, Radiation, Chemotherapy & Hormone Therapy	Surgery, Chemotherapy & Hormone Therapy	Other Specified Therapy	No 1st Course Treatment
<b>My Facility</b>	27.42 % (n=17)	8.06 % (n=5)	6.45 % (n=4)	6.45 % (n=4)	29.03 % (n=18)	8.06 % (n=5)	8.06 % (n=5)	3.23 % (n=2)	1.61 % (n=1)	0 % (n=0)
<b>All CoC</b>	14.58 % (n=13275)	8.48 % (n=7723)	5.64 % (n=5133)	5.66 % (n=5150)	32.33 % (n=29445)	17.69 % (n=16106)	6.19 % (n=5636)	3.88 % (n=3537)	2.8 % (n=2547)	1.66 % (n=1509)



# Days to First Treatment Quartiles Breast Cancer: Cases Diagnosed and Treated at My Facility, 2012



	0-15	16-28	29-42	>=43
My Facility	26.67 % (n=24)	37.78 % (n=34)	24.44 % (n=22)	11.11 % (n=10)

Percent for my facility represents what percent of our patients were treated within the number of days in this table. The "national" benchmarks for CoC-accredited programs are represented by the Quartiles represented in the column.



AMERICAN COLLEGE OF SURGEONS  
Inspiring Quality.  
Highest Standards. Better Outcomes

100+ years


CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

# Days to First Treatment Quartiles Breast Cancer: Cases Diagnosed at My Facility or Elsewhere; Treated at My Facility, 2012




	0-15	16-28	29-42	>=43
My Facility	25.19 % (n=33)	41.98 % (n=55)	22.14 % (n=29)	10.69 % (n=14)

Percent for my facility represents what percent of our patients were treated within the number of days in this table. The "national" benchmarks for CoC-accredited programs are represented by the Quartiles represented in the column.



# Zip Code Location of Radiation Delivery for Breast Cancer Heat Map, 2012



	At My Facility	Elsewhere	Total	Average Distance for All Pts
<b>Patients Radiated</b>	92% (n=69)	8% (n=6)	75	18.09

\* n/d = Number of cases in zip code that received radiation in my facility / Number of cases in zip code that received radiation



AMERICAN COLLEGE OF SURGEONS  
Inspiring Quality.  
Highest Standards. Better Outcomes

100+ years

CQIP

Cancer Quality Improvement Program




© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

# Colon Cancer—Additional Reports

- Stage Distribution
- In/Out Migration
- In/Out Migration by Insurance Status
- Insurance Status
- Distance Traveled
- Days to First Treatment: Cases Diagnosed and Treated at My Facility
- Days to First Treatment: Cases Diagnosed at My Facility or Elsewhere; Treated at My Facility



# Stage Distribution - Colon Cancer Diagnosed in 2012, My Facility vs. All CoC




	0	I	II	III	IV	NA	UNK
<b>My Facility</b>	9.23 % (n=6)	15.38 % (n=10)	20 % (n=13)	26.15 % (n=17)	13.85 % (n=9)	0 % (n=0)	15.38 % (n=10)
<b>All CoC</b>	5.77 % (n=4266)	19.4 % (n=14351)	24.27 % (n=17956)	24.73 % (n=18294)	19.85 % (n=14686)	0.12 % (n=87)	5.88 % (n=4349)






# In/Out Migration Colon Cancer, 2010 - 2012 - My Facility



	2010	2011	2012
<b>Diagnosed Here and Treated Elsewhere</b>	2.04 % (n=1)	7.25 % (n=5)	3.08 % (n=2)
<b>Diagnosed and Treated Here</b>	83.67 % (n=41)	69.57 % (n=48)	67.69 % (n=44)
<b>Diagnosed Elsewhere and Treated Here</b>	14.29 % (n=7)	23.19 % (n=16)	29.23 % (n=19)

# In/Out Migration by Insurance Status - Colon Cancer, 2012

## My Facility




	Not Insured	Private/Managed	Medicaid	Medicare	Other Government	Unknown
Diagnosed Here and Treated Elsewhere	0 % (n=0)	0 % (n=0)	0 % (n=0)	1.5 % (n=1)	0 % (n=0)	1.5 % (n=1)
Diagnosed and Treated Here	0 % (n=0)	13.8 % (n=9)	1.5 % (n=1)	52.3 % (n=34)	0 % (n=0)	0 % (n=0)
Diagnosed Elsewhere and Treated Here	1.5 % (n=1)	10.8 % (n=7)	0 % (n=0)	16.9 % (n=11)	0 % (n=0)	0 % (n=0)



# Insurance Status - Colon Cancer, 2009 - 2012


## My Facility vs. All CoC



	2009 My Facility	2010 My Facility	2011 My Facility	2012 My Facility	2012 All CoC
<b>Not Insured</b>	3.13 % (n=2)	10.2 % (n=5)	1.45 % (n=1)	1.54 % (n=1)	3.85 % (n=2715)
<b>Private/Managed</b>	34.38 % (n=22)	24.49 % (n=12)	18.84 % (n=13)	24.62 % (n=16)	31.45 % (n=22169)
<b>Medicaid</b>	3.13 % (n=2)	8.16 % (n=4)	1.45 % (n=1)	1.54 % (n=1)	5.05 % (n=3563)
<b>Medicare</b>	56.25 % (n=36)	57.14 % (n=28)	75.36 % (n=52)	70.77 % (n=46)	55.44 % (n=39088)
<b>Other Government</b>	0 % (n=0)	0 % (n=0)	0 % (n=0)	0 % (n=0)	2.49 % (n=1756)
<b>Insurance Status Unknown</b>	3.13 % (n=2)	0 % (n=0)	2.9 % (n=2)	1.54 % (n=1)	1.71 % (n=1208)




# Distance Traveled - Colon Cancer, 2012



	< 5 miles	5-9 miles	10-24 miles	25-49 miles	50-99 miles	>=100 miles	Unknown
My Facility	10.77 % (n=7)	23.08 % (n=15)	43.08 % (n=28)	23.08 % (n=15)	0 % (n=0)	0 % (n=0)	0 % (n=0)
All CoC	22.11 % (n=15588)	24.58 % (n=17331)	29.56 % (n=20837)	12.85 % (n=9057)	6.57 % (n=4631)	3.84 % (n=2704)	0.5 % (n=351)

# Days to First Treatment 50th Percentile Colon Cancer: Cases Diagnosed and Treated at My Facility, 2012



	0-6	>=7
<b>My Facility</b>	46.88 % (n=15)	53.13 % (n=17)

Percent for my facility represents what percent of our patients were treated within the number of days in this table. The "national" benchmarks for CoC-accredited programs are represented by the 50th Percentile represented in the column.



AMERICAN COLLEGE OF SURGEONS  
Inspiring Quality.  
Highest Standards. Better Outcomes

100+ years


CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

# Days to First Treatment 50th Percentile Colon Cancer: Cases Diagnosed at My Facility or Elsewhere; Treated at My Facility, 2012



	0-6	>=7
My Facility	45.83 % (n=22)	54.17 % (n=26)

Percent for my facility represents what percent of our patients were treated within the number of days in this table. The "national" benchmarks for CoC-accredited programs are represented by the 50th Percentile represented in the column.




# Non-Small-Cell Lung Cancer (NSCLC)—Additional Reports

- Stage Distribution
- In/Out Migration Cancer
- In/Out Migration by Insurance Status
- Insurance Status
- Distance Traveled
- First Course of Treatment Stage I
- Days to First Treatment: Cases Diagnosed and Treated at My Facility
- Days to First Treatment: Cases Diagnosed at My Facility or Elsewhere; Treated at My Facility



# Stage Distribution - Non Small Cell Lung Cancer Diagnosed in 2012, My Facility vs. All CoC




	0	I	II	III	IV	OC	NA	UNK
<b>My Facility</b>	2.11 % (n=2)	28.42 % (n=27)	5.26 % (n=5)	26.32 % (n=25)	36.84 % (n=35)	0 % (n=0)	0 % (n=0)	1.05 % (n=1)
<b>All CoC</b>	0.43 % (n=543)	26.08 % (n=32629)	9.67 % (n=12095)	19.78 % (n=24748)	40.01 % (n=50060)	0.15 % (n=191)	0 % (n=1)	3.87 % (n=4843)






# In/Out Migration Non-Small Cell Lung Cancer, 2010 - 2012 - My Facility



	2010	2011	2012
<b>Diagnosed Here and Treated Elsewhere</b>	13.83 % (n=13)	14.63 % (n=12)	8.42 % (n=8)
<b>Diagnosed and Treated Here</b>	73.4 % (n=69)	62.2 % (n=51)	69.47 % (n=66)
<b>Diagnosed Elsewhere and Treated Here</b>	12.77 % (n=12)	23.17 % (n=19)	22.11 % (n=21)



# In/Out Migration by Insurance Status Non-Small Cell Lung Cancer, 2012 - My Facility




	Not Insured	Private/Managed	Medicaid	Medicare	Other Government	Unknown
Diagnosed Here and Treated Elsewhere	2.1 % (n=2)	1.1 % (n=1)	0 % (n=0)	5.3 % (n=5)	0 % (n=0)	0 % (n=0)
Diagnosed and Treated Here	5.3 % (n=5)	11.6 % (n=11)	3.2 % (n=3)	45.3 % (n=43)	0 % (n=0)	4.2 % (n=4)
Diagnosed Elsewhere and Treated Here	3.2 % (n=3)	3.2 % (n=3)	0 % (n=0)	15.8 % (n=15)	0 % (n=0)	0 % (n=0)



# Insurance Status - Non-Small Cell Lung Cancer, 2009 - 2012


## My Facility vs. All CoC



	2009 My Facility	2010 My Facility	2011 My Facility	2012 My Facility	2012 All CoC
<b>Not Insured</b>	7.69 % (n=7)	6.38 % (n=6)	9.76 % (n=8)	10.53 % (n=10)	3.42 % (n=4282)
<b>Private/Managed</b>	23.08 % (n=21)	31.91 % (n=30)	19.51 % (n=16)	15.79 % (n=15)	24.67 % (n=30866)
<b>Medicaid</b>	1.1 % (n=1)	2.13 % (n=2)	3.66 % (n=3)	3.16 % (n=3)	6.15 % (n=7693)
<b>Medicare</b>	67.03 % (n=61)	57.45 % (n=54)	64.63 % (n=53)	66.32 % (n=63)	60.32 % (n=75465)
<b>Other Government</b>	0 % (n=0)	0 % (n=0)	0 % (n=0)	0 % (n=0)	3.38 % (n=4226)
<b>Insurance Status Unknown</b>	1.1 % (n=1)	2.13 % (n=2)	2.44 % (n=2)	4.21 % (n=4)	2.06 % (n=2578)




# Distance Traveled - Non-Small Cell Lung Cancer, 2012



	< 5 miles	5-9 miles	10-24 miles	25-49 miles	50-99 miles	>=100 miles	Unknown
My Facility	20 % (n=19)	23.16 % (n=22)	33.68 % (n=32)	21.05 % (n=20)	2.11 % (n=2)	0 % (n=0)	0 % (n=0)
All CoC	19.1 % (n=23898)	21.99 % (n=27507)	28.73 % (n=35938)	15.98 % (n=19991)	8.8 % (n=11005)	4.93 % (n=6173)	0.48 % (n=598)

# First Course Treatment Stage I Non-Small Cell Lung Cancer, 2012


## My Facility vs. All CoC



	Surgery Only	Radiation Only	Surgery & Chemotherapy	Radiation & Chemotherapy	Chemotherapy Only	Surgery, Radiation & Chemotherapy	Other Specified Therapy	No 1st Course Treatment
<b>My Facility</b>	55.56 % (n=15)	25.93 % (n=7)	0 % (n=0)	0 % (n=0)	14.81 % (n=4)	0 % (n=0)	0 % (n=0)	3.7 % (n=1)
<b>All CoC</b>	58.81 % (n=19190)	20.52 % (n=6696)	3.81 % (n=1243)	2.98 % (n=972)	1.41 % (n=461)	1.33 % (n=434)	1.46 % (n=477)	7.82 % (n=2552)



# Days to First Treatment Quartiles Non-Small Cell Lung Cancer: Cases Diagnosed and Treated at My Facility, 2012




	0-10	11-27	28-48	>=49
My Facility	19.51 % (n=8)	26.83 % (n=11)	26.83 % (n=11)	26.83 % (n=11)

Percent for my facility represents what percent of our patients were treated within the number of days in this table. The "national" benchmarks for CoC-accredited programs are represented by the Quartiles represented in the column.



# Days to First Treatment Quartiles Non-Small Cell Lung Cancer: Cases Diagnosed at My Facility or Elsewhere; Treated at My Facility, 2012



	0-10	11-27	28-48	>=49
My Facility	20.69 % (n=12)	31.03 % (n=18)	22.41 % (n=13)	25.86 % (n=15)

Percent for my facility represents what percent of our patients were treated within the number of days in this table. The "national" benchmarks for CoC-accredited programs are represented by the Quartiles represented in the column.



AMERICAN COLLEGE OF SURGEONS  
Inspiring Quality.  
Highest Standards. Better Outcomes

100+ years

CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

# Prostate Cancer—Additional Reports


- Stage Distribution
- In/Out Migration
- In/Out Migration by Insurance Status
- Insurance Status
- Distance Traveled
- First Course of Treatment Stage I and II
- Days to First Treatment: Cases Diagnosed and Treated at My Facility
- Days to First Treatment: Cases Diagnosed at My Facility or Elsewhere; Treated at My Facility





# Stage Distribution - Prostate Cancer Diagnosed in 2012


## My Facility vs. All CoC



	I	II	III	IV	NA	UNK
My Facility	29.73 % (n=22)	58.11 % (n=43)	5.41 % (n=4)	5.41 % (n=4)	0 % (n=0)	1.35 % (n=1)
All CoC	22.44 % (n=24181)	55.98 % (n=60309)	10.86 % (n=11699)	7.78 % (n=8382)	0.05 % (n=56)	2.88 % (n=3108)




# In/Out Migration Prostate Cancer, 2010 - 2012 - My Facility



	2010	2011	2012
<b>Diagnosed Here and Treated Elsewhere</b>	0 % (n=0)	1.2 % (n=1)	2.7 % (n=2)
<b>Diagnosed and Treated Here</b>	81.69 % (n=58)	79.52 % (n=66)	56.76 % (n=42)
<b>Diagnosed Elsewhere and Treated Here</b>	18.31 % (n=13)	19.28 % (n=16)	40.54 % (n=30)

# In/Out Migration by Insurance Status Prostate Cancer, 2012

## My Facility




	Not Insured	Private/Managed	Medicaid	Medicare	Other Government	Unknown
Diagnosed Here and Treated Elsewhere	0 % (n=0)	1.4 % (n=1)	0 % (n=0)	1.4 % (n=1)	0 % (n=0)	0 % (n=0)
Diagnosed and Treated Here	0 % (n=0)	20.3 % (n=15)	1.4 % (n=1)	35.1 % (n=26)	0 % (n=0)	0 % (n=0)
Diagnosed Elsewhere and Treated Here	0 % (n=0)	20.3 % (n=15)	0 % (n=0)	18.9 % (n=14)	1.4 % (n=1)	0 % (n=0)



# Insurance Status - Prostate Cancer, 2009-2012


## My Facility vs. All CoC



	2009 My Facility	2010 My Facility	2011 My Facility	2012 My Facility	2012 All CoC
<b>Not Insured</b>	2.94 % (n=2)	4.23 % (n=3)	3.61 % (n=3)	0 % (n=0)	2.38 % (n=2564)
<b>Private/Managed</b>	30.88 % (n=21)	38.03 % (n=27)	34.94 % (n=29)	41.89 % (n=31)	44.08 % (n=47486)
<b>Medicaid</b>	1.47 % (n=1)	2.82 % (n=2)	0 % (n=0)	1.35 % (n=1)	2.77 % (n=2980)
<b>Medicare</b>	64.71 % (n=44)	52.11 % (n=37)	60.24 % (n=50)	55.41 % (n=41)	43.02 % (n=46349)
<b>Other Government</b>	0 % (n=0)	2.82 % (n=2)	0 % (n=0)	1.35 % (n=1)	5.58 % (n=6012)
<b>Insurance Status Unknown</b>	0 % (n=0)	0 % (n=0)	1.2 % (n=1)	0 % (n=0)	2.18 % (n=2344)




# Distance Traveled - Prostate Cancer, 2012 - My Facility



	< 5 miles	5-9 miles	10-24 miles	25-49 miles	50-99 miles	>=100 miles	Unknown
<b>My Facility</b>	20.27 % (n=15)	14.86 % (n=11)	33.78 % (n=25)	25.68 % (n=19)	1.35 % (n=1)	0 % (n=0)	4.05 % (n=3)
<b>All CoC</b>	14.75 % (n=15893)	19.14 % (n=20623)	30.31 % (n=32659)	16.6 % (n=17883)	9.66 % (n=10404)	8.77 % (n=9448)	0.77 % (n=825)


# First Course Treatment Stage I & II Prostate Cancer, 2012 My Facility vs. All CoC



	Surgery Only	Radiation Only	Surgery & Radiation	Radiation & Hormone Therapy	Active Surveillance	No 1st Course Treatment
<b>Stage I - My Facility</b>	81.82 % (n=18)	4.55 % (n=1)	9.09 % (n=2)	0 % (n=0)	4.55 % (n=1)	0 % (n=0)
<b>Stage I - All CoC</b>	35.23 % (n=8518)	27.83 % (n=6729)	0.95 % (n=229)	4.7 % (n=1136)	17.29 % (n=4182)	10.27 % (n=2484)
<b>Stage II - My Facility</b>	69.77 % (n=30)	4.65 % (n=2)	4.65 % (n=2)	18.6 % (n=8)	0 % (n=0)	2.33 % (n=1)
<b>Stage II - All CoC</b>	54.26 % (n=32725)	16.09 % (n=9702)	0.9 % (n=540)	15.01 % (n=9052)	2.87 % (n=1731)	4.72 % (n=2844)



# Days to First Treatment Quartiles Prostate Cancer: Cases Diagnosed and Treated at My Facility, 2012



	0-32	33-60	61-91	>=92
My Facility	45.95 % (n=17)	43.24 % (n=16)	8.11 % (n=3)	2.7 % (n=1)

Percent for my facility represents what percent of our patients were treated within the number of days in this table. The "national" benchmarks for CoC-accredited programs are represented by the Quartiles represented in the column.



AMERICAN COLLEGE OF SURGEONS  
Inspiring Quality.  
Highest Standards. Better Outcomes

100+ years


CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

# Days to First Treatment Quartiles Prostate Cancer: Cases Diagnosed at My Facility or Elsewhere; Treated at My Facility, 2012



	0-32	33-60	61-91	>=92
My Facility	30.3 % (n=20)	36.36 % (n=24)	18.18 % (n=12)	15.15 % (n=10)

Percent for my facility represents what percent of our patients were treated within the number of days in this table. The "national" benchmarks for CoC-accredited programs are represented by the Quartiles represented in the column.






# Melanoma of the Skin Cancer—Additional Reports

- Stage Distribution
- In/Out Migration
- In/Out Migration by Insurance Status
- Insurance Status
- Distance Traveled
- Days to First Treatment: Cases Diagnosed and Treated at My Facility
- Days to First Treatment: Cases Diagnosed at My Facility or Elsewhere; Treated at My Facility



# Stage Distribution - Melanoma Cancer Diagnosed in 2012


## My Facility vs. All CoC



	0	I	II	III	IV	NA	UNK
My Facility	52.38 % (n=11)	19.05 % (n=4)	4.76 % (n=1)	9.52 % (n=2)	9.52 % (n=2)	0 % (n=0)	4.76 % (n=1)
All CoC	26.12 % (n=12388)	43.06 % (n=20419)	12.91 % (n=6124)	8.51 % (n=4034)	4.33 % (n=2052)	0.01 % (n=4)	5.06 % (n=2398)




# In/Out Migration Melanoma Cancer, 2010 - 2012 - My Facility



	2010	2011	2012
<b>Diagnosed Here and Treated Elsewhere</b>	0 % (n=0)	9.09 % (n=1)	0 % (n=0)
<b>Diagnosed and Treated Here</b>	50 % (n=9)	72.73 % (n=8)	14.29 % (n=3)
<b>Diagnosed Elsewhere and Treated Here</b>	50 % (n=9)	18.18 % (n=2)	85.71 % (n=18)



# In/Out Migration by Insurance Status Melanoma Cancer, 2012 My Facility




	Not Insured	Private/Managed	Medicaid	Medicare	Other Government	Unknown
Diagnosed Here and Treated Elsewhere	0 % (n=0)	0 % (n=0)	0 % (n=0)	0 % (n=0)	0 % (n=0)	0 % (n=0)
Diagnosed and Treated Here	0 % (n=0)	9.5 % (n=2)	0 % (n=0)	4.8 % (n=1)	0 % (n=0)	0 % (n=0)
Diagnosed Elsewhere and Treated Here	4.8 % (n=1)	23.8 % (n=5)	0 % (n=0)	57.1 % (n=12)	0 % (n=0)	0 % (n=0)



# Insurance Status - Melanoma Cancer, 2009 - 2012


## My Facility vs. All CoC



	2009 My Facility	2010 My Facility	2011 My Facility	2012 My Facility	2012 All CoC
<b>Not Insured</b>	0 % (n=0)	0 % (n=0)	0 % (n=0)	4.76 % (n=1)	2.53 % (n=1200)
<b>Private/ Managed</b>	66.67 % (n=6)	77.78 % (n=14)	54.55 % (n=6)	33.33 % (n=7)	47.97 % (n=22746)
<b>Medicaid</b>	0 % (n=0)	0 % (n=0)	0 % (n=0)	0 % (n=0)	0 % (n=0)
<b>Medicare</b>	33.33 % (n=3)	22.22 % (n=4)	45.45 % (n=5)	61.9 % (n=13)	41.32 % (n=19592)
<b>Other Government</b>	0 % (n=0)	0 % (n=0)	0 % (n=0)	0 % (n=0)	0 % (n=0)
<b>Insurance Status Unknown</b>	0 % (n=0)	0 % (n=0)	0 % (n=0)	0 % (n=0)	0 % (n=0)




# Distance Traveled - Melanoma Cancer, 2012 - My Facility



	< 5 miles	5-9 miles	10-24 miles	25-49 miles	50-99 miles	>=100 miles	Unknown
My Facility	4.76 % (n=1)	4.76 % (n=1)	38.1 % (n=8)	52.38 % (n=11)	0 % (n=0)	0 % (n=0)	0 % (n=0)
All CoC	12.24 % (n=5806)	17.05 % (n=8085)	32.5 % (n=15410)	19.19 % (n=9102)	11.33 % (n=5372)	7.3 % (n=3463)	0.38 % (n=181)

# Days to First Treatment 90th Percentile Melanoma Cancer: Cases Diagnosed and Treated at My Facility, 2012



	0-40	>=41
<b>My Facility</b>	33.33 % (n=1)	66.67 % (n=2)

Percent for my facility represents what percent of our patients were treated within the number of days in this table. The "national" benchmarks for CoC-accredited programs are represented by the 90th Percentile represented in the column.



AMERICAN COLLEGE OF SURGEONS  
Inspiring Quality.  
Highest Standards. Better Outcomes

100+ years


CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

# Days to First Treatment 90th Percentile Melanoma Cancer: Cases Diagnosed at My Facility or Elsewhere; Treated at My Facility, 2012



	0-40	≥41
My Facility	88.24 % (n=15)	11.76 % (n=2)

Percent for my facility represents what percent of our patients were treated within the number of days in this table. The "national" benchmarks for CoC-accredited programs are represented by the 90th Percentile represented in the column.



AMERICAN COLLEGE OF SURGEONS  
Inspiring Quality.  
Highest Standards. Better Outcomes

100+ years

CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.



# Commission on Cancer

- Established by the American College of Surgeons (ACoS) in 1922
- A consortium of professional organizations dedicated to improving survival and quality of life for cancer patients
- Sets standards to ensure quality, multidisciplinary, and comprehensive cancer care delivery in health care settings
- Conducts surveys to assess compliance with those standards
- Collects standardized data to measure cancer care quality
- Uses data to monitor treatment patterns and outcomes and enhance cancer control and clinical surveillance activities
- Develops educational interventions to improve cancer prevention, early detection, cancer-care delivery, and outcomes




# Commission on Cancer: The Value of Accreditation

- **Demonstrates commitment** to patients, communities, providers, payers, and policymakers to improving survival and quality of life for patients and to evidence-based, organized, comprehensive, and quality cancer care
- **Standards ensure that state-of-the-art** clinical services for diagnosing, treating, rehabilitating, and supporting cancer patients and their families are available to provide **quality care**
- **National Cancer Data Base** participation by cancer registries captures more than 100 data elements for every patient and more than 70% of all new cancer patients diagnosed in the U.S. each year. Participant User File (PUF) access for research is only available to investigators at CoC-approved programs
- **Measuring quality and outcomes**, including overall survival, through a rapidly expanding panel of quality measures for cancers of the breast, colon, rectum, lung, esophagus, and stomach, and soon to include gynecologic and urologic malignancies, melanoma, sarcoma and pediatric tumors. Comparison with nation-wide data from all 1,500 CoC-accredited programs
- **Ensures a multidisciplinary team approach** including information and access to clinical trials, access to prevention and early detection programs, cancer conferences, and oversight by a Cancer Committee



# Commission on Cancer - Accredited Programs By State



AMERICAN COLLEGE OF SURGEONS  
Inspiring Quality.  
Highest Standards. Better Outcomes

100+years

CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

# Role of the Cancer Liaison Physician (CLP)

CLPs monitor the performance of their Cancer Program to address challenges and opportunities using information from the following NCDB Tools that include:

Accountability Measures  
Quality Improvement Measures  
Surveillance Measures  
Survival Reports

Cancer Program Profile Practice Reports (CP3R)  
Cancer Quality Improvement Program (CQIP)  
Hospital Comparison Benchmark Reports (HCBM)  
Rapid Quality Reporting System (RQRS)

***Standard 4.3*** *Role of the Cancer Liaison Physician - A Cancer Liaison Physician serves in a leadership role within the cancer program, and is responsible for evaluating, interpreting and reporting the program's performance using the National Cancer Data Base (NCDB) data. The CLP reports the results of this analysis to the cancer committee at least four times a year.*

## **CQIP – A Resource for the Cancer Liaison Physician Reporting to Cancer Committee**



# Commission on Cancer Member Organizations

- Academy of Nutrition and Dietetics (AND)
- Alliance for Clinical Trials in Oncology (ALLIANCE)
- American Academy of Hospice and Palliative Medicine (AAHPM)
- American Academy of Pediatrics (AAP)
- American Association for Cancer Education (AAE)
- American Cancer Society (ACS)
- American College of Obstetricians and Gynecologists (ACOG)
- American College of Oncology Administrators (ACOA)
- American College of Physicians (ACP)
- American College of Radiology (ACR)
- American College of Surgeons Resident and Associate Society (ACOSRAS)
- American College of Surgeons Young Fellows Association (ACOSYFA)
- American Head and Neck Society (AHNS)
- American Hospital Association (AHA)
- American Joint Committee on Cancer (AJCC)
- American Medical Association (AMA)
- American Pediatric Surgical Association (APSA)
- American Physical Therapy Association (APTA)
- American Psychosocial Oncology Society (APOS)
- American Radium Society (ARS)
- American Society of Breast Surgeons (ASBS)
- American Society of Clinical Oncology (ASCO)
- American Society of Colon and Rectal Surgeons (ASCRS)
- American Society of Plastic Surgeons (ASPS)
- American Society of Radiation Oncology (ASTRO)
- American Urological Association (AUA)
- Association of American Cancer Institutes (AACI)
- Association of Cancer Executives (ACE)
- Association of Community Cancer Centers (ACCC)
- Association of Oncology Social Work (AOSW)
- Cancer Support Community (CSC)
- Centers for Disease Control and Prevention (CDC)
- College of American Pathologists (CAP)
- Community Oncology Alliance (COA)
- Department of Defense (DOD)
- Department of Veterans Affairs (VA)
- Hematology/Oncology Pharmacy Association (HOPA)
- LIVESTRONG (Lance Armstrong Foundation)
- National Accreditation Program for Breast Centers (NAPBC)
- National Cancer Institute (NCI)
  - Applied Research Program
  - SEER Program
- National Cancer Registrars Association (NCRA)
- National Coalition for Cancer Survivorship (NCCS)
- National Comprehensive Cancer Network (NCCN)
- National Consortium of Breast Centers (NCBC)
- National Society of Genetic Counselors (NSGC)
- National Surgical Adjuvant Breast and Bowel Project (NSABP)
- North American Association of Central Cancer Registries (NAACCR)
- Oncology Nursing Society (ONS)
- Society of Gynecologic Oncology (SGO)
- Society of Nuclear Medicine and Molecular Imaging (SNMMI)
- Society of Surgical Oncology (SSO)
- Society of Thoracic Surgeons (STS)



# National Cancer Data Base (NCDB)

- A joint program of the CoC and the American Cancer Society that began in 1988
- A nationwide oncology database for more than 1,500 CoC-accredited U.S. cancer programs
- 70 percent of all newly diagnosed U.S. cancer cases are captured at the facility level and reported
- Contains approximately 32 million records from hospital cancer registries across the U.S.



# American College of Surgeons: 100 Years of Quality Improvement



AMERICAN COLLEGE OF SURGEONS  
Inspiring Quality:  
Highest Standards, Better Outcomes

100+years

CQIP


Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

# The American College of Surgeons and The American Cancer Society

*Partners to Improve the Lives of Cancer Patients*



The Commission on Cancer acknowledges the support of the American Cancer Society for their support of the National Cancer Data Base and the Cancer Liaison Physician Program



AMERICAN COLLEGE OF SURGEONS  
Inspiring Quality:  
Highest Standards, Better Outcomes

100+years

CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.



# Acknowledgements

## **American College of Surgeons Commission on Cancer**

Daniel P. McKellar, MD, FACS, Chair  
David P. Winchester, MD, FACS, Medical Director, Cancer Programs  
Ryan McCabe PhD Senior Manager, National Cancer Database

## **Commission on Cancer Committee Leadership 2013 - 2014**

### **Accreditation**

Linda W. Ferris PhD, Chair  
Danny Takanishi, MD, FACS, Vice-Chair

### **Cancer Liaison**

Philip Y. Roland, MD, FACS, FACOG, Chair  
Mary J. Milroy, MD, FACS, Vice-Chair

### **Education**

Howard L. Kaufman, MD, FACS, Chair  
Patrick Ross, MD, FACS, Vice-Chair

### **Member Organizations**

Virginia Vaitones, MSW, OSW-C, Chair  
Carma Herring, Vice-Chair

### **Quality Integration**

Lawrence N. Shulman, MD,, FACP Chair  
Ned Carp, MD, FACS Vice-Chair

## **CQIP**

Lawrence N. Shulman, MD, CQIP Project Director  
Kenneth Pristas, CQIP Project Manager, MSHI, PMP  
Christopher M. Pezzi, MD, FACS, CQIP Project Consultant

## **CQIP/NCDB Staff**

Greer Gay, Ph.D, RN  
Florin Petrescu, MS  
Dennis Harman, MS  
Bryan Palis, MA  
Katherine Mallin, Ph.D  
Ashley Loomis, MPH  
Kenneth Pristas, MSHI, PMP

## **Further Assistance**

Kenneth Pristas, MSHI, PMP  
CQIP Project Manager  
Phone: 312-202-5451  
Email: [kpristas@facs.org](mailto:kpristas@facs.org)

## **CQIP Email**

[ncdbcqip@facs.org](mailto:ncdbcqip@facs.org)





AMERICAN COLLEGE OF SURGEONS

*Inspiring Quality:*

*Highest Standards, Better Outcomes*

100+years

CQIP

Cancer Quality Improvement Program



Commission  
on Cancer®

# CQIP

## Cancer Quality Improvement Program

**Commission on Cancer**

[www.facs.org/quality-programs/cancer/coc](http://www.facs.org/quality-programs/cancer/coc)

312-202-5085

**CQIP**

[www.facs.org/quality-programs/cancer/ncdb/qualitytools/cqip](http://www.facs.org/quality-programs/cancer/ncdb/qualitytools/cqip)